SecBot SecBot
SECBOTREPLAY Home › Report › WVE

WVE · Wave Life Sciences reported Q1 2026 revenue of $38.2M (vs consensus…

Wave Life Sciences USA, Inc. · PRESS-RELEASE filed Apr 28, 2026 at 07:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 28, 2026 at 07:30 ET

Wave Life Sciences reported Q1 2026 revenue of $38.2M (vs consensus $7.9M) and EPS of -$0.13 (vs consensus -$0.31), representing a massive beat. Net loss improved to $26.1M from $46.9M a year ago, and the company maintained a strong cash position of $544.6M. Pipeline catalysts include FDA acceptance of WVE-007 Phase 2a and upcoming AATD data.

  • Q1 2026 revenue $38.2M vs consensus $7.9M (beat by 384%)
  • Q1 2026 EPS -$0.13 vs consensus -$0.31 (beat by 58%)
  • Net loss improved to $26.1M from $46.9M YoY
  • Cash and equivalents $544.6M, runway into Q3 2028

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access